Fusion Pharmaceuticals (Fusion Pharmaceuticals) Total Stockholders Equity : $241.83 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Fusion Pharmaceuticals Total Stockholders Equity?

Fusion Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $241.83 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Fusion Pharmaceuticals's Book Value per Share for the quarter that ended in Mar. 2024 was $2.85. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Fusion Pharmaceuticals's Debt-to-Equity for the quarter that ended in Mar. 2024 was 0.27.

Fusion Pharmaceuticals Total Stockholders Equity Historical Data

The historical data trend for Fusion Pharmaceuticals's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fusion Pharmaceuticals Total Stockholders Equity Chart

Fusion Pharmaceuticals Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

Get a 7-Day Free Trial

-33.49

294.51

231.46

162.22

222.48

Fusion Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Stockholders Equity	Get a 7-Day Free Trial															200.83	202.96	188.47	222.48	241.83

Fusion Pharmaceuticals (NAS:FUSN) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Fusion Pharmaceuticals's Book Value per Share for the quarter that ended in Mar. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(241.831	-	0)	/	84.865
	=	2.85

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Fusion Pharmaceuticals's Debt-to-Equity for the quarter that ended in Mar. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4.288	+	60.259)	/	241.831
	=	0.27

Fusion Pharmaceuticals Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Fusion Pharmaceuticals's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Fusion Pharmaceuticals (Fusion Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fusion Pharmaceuticals Inc (NAS:FUSN) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

270 Longwood Road South, Hamilton, ON, CAN, L8P 0A6

Website

https://www.fusionpharma.com

Fusion Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing alpha therapeutics for curing cancer. It develops Targeted Alpha Therapies (TAT) together with its proprietary Fast-Clear linker technology. The firm's lead product candidate comprises FPI-1434, a monotherapy for the treatment of a variety of cancers; FPI-1966, for the treatment of head and neck and bladder cancers; and FPI-2059 among others.

Executives

Teresa Marie Bitetti	director	40 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Jeremy Bender	director	395 OYSTER POINT BLVD., SUITE 217, SOUTH SAN FRANCISCO CA 94080
David D. Meek	director	3000 KENT AVENUE; SUITE A1-100, WEST LAFAYETTE IN 47906
Dmitri Bobilev	officer: Chief Medical Officer	C/O FUSION PHARMACEUTICALS INC., 270 LONGWOOD RD. SOUTH, HAMILTON Z4 L8P 0A6
Steven Gannon	director	C/O XENON PHARMACEUTICALS INC., 200 - 3650 GILMORE WAY, BURNABY A0 V5G 4W8
John Valliant	director, officer: Chief Executive Officer	FUSION PHARMACEUTICALS INC., 270 LONGWOOD ROAD SOUTH, HAMILTON A6 L8P 0A6
Christopher P Leamon	officer: Chief Scientific Officer	C/O FUSION PHARMACEUTICALS INC., 2 INTERNATIONAL PLACE SUITE 2310, BOSTON MA 02110
Mohit Rawat	officer: President and CBO	FUSION PHARMACEUTICALS INC., 270 LONGWOOD ROAD SOUTH, HAMILTON D0 L8P 0A6
Donald A Bergstrom	director	840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Philina Lee	director	C/O FUSION PHARMACEUTICALS, INC., 270 LONGWOOD ROAD SOUTH, HAMILTON D0 L8P OA6
Adams Street Partners Llc	10 percent owner	ONE NORTH WACKER DRIVE, STE 2700, CHICAGO IL 60606-2807
Barbara Gayle Duncan	director	C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES STREET, NEW YORK NY 10013
John J Crowley	officer: Chief Financial Officer	251 BALLARDVALE STREET, WILMINGTON MA 01887
Healthcap Vii, L.p.	10 percent owner	18 AVENUE D'OUCHY, CH 1006 LAUSANNE V8 1000-1018
James J O'leary	officer: Chief Medical Officer	830 WINTER STREET, WALTHAM MA 02452